Literature DB >> 27378193

Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.

Jorge J Castillo1, Ramon Garcia-Sanz2, Evdoxia Hatjiharissi3, Robert A Kyle4, Xavier Leleu5, Mary McMaster6, Giampaolo Merlini7, Monique C Minnema8, Enrica Morra9, Roger G Owen10, Stephanie Poulain11, Marvin J Stone12, Constantine Tam13, Marzia Varettoni14, Meletios A Dimopoulos15, Steven P Treon16, Efstathios Kastritis15.   

Abstract

The diagnosis of Waldenström macroglobulinaemia (WM) can be challenging given the variety of signs and symptoms patients can present. Furthermore, once the diagnosis of WM is established, the initial evaluation should be thorough as well as appropriately directed. During the 8th International Workshop for WM in London, United Kingdom, a multi-institutional task force was formed to develop consensus recommendations for the diagnosis and initial evaluation of patients with WM. In this document, we present the results of the deliberations that took place to address these issues. We provide recommendations for history-taking and physical examination, laboratory studies, bone marrow aspiration and biopsy analysis and imaging studies. We also provide guidance on the initial evaluation of special situations, such as anaemia, hyperviscosity, neuropathy, Bing-Neel syndrome and amyloidosis. We hope these recommendations serve as a practical guidance to clinicians taking care of patients with a suspected or an established diagnosis of WM.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  Bing-Neel syndrome; Waldenström macroglobulinaemia; amyloidosis; anaemia; hyperviscosity; neuropathy

Mesh:

Year:  2016        PMID: 27378193      PMCID: PMC5154335          DOI: 10.1111/bjh.14196

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  55 in total

Review 1.  Evidence-based focused review of management of hyperviscosity syndrome.

Authors:  Marvin J Stone; Steven A Bogen
Journal:  Blood       Date:  2011-12-06       Impact factor: 22.113

2.  Autoimmune hemolytic anemias and IgG antierythrocyte autoantibodies in Waldenström's macroglobulinemia: association with FcgammaRIIa polymorphism.

Authors:  S Poulain; I Dervite; X Leleu; J Fernandes; L Stalnikiewicz; A-S Moreau; V Coiteux; S de Botton; P Duthilleul; P Morel
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

3.  Peripheral neuropathies in Waldenström's macroglobulinaemia.

Authors:  T Levine; A Pestronk; J Florence; M T Al-Lozi; G Lopate; T Miller; I Ramneantu; W Waheed; M Stambuk; M J Stone; R Choksi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

4.  Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia.

Authors:  Stéphanie Poulain; Christophe Roumier; Aurélie Venet-Caillault; Martin Figeac; Charles Herbaux; Guillemette Marot; Emmanuelle Doye; Elisabeth Bertrand; Sandrine Geffroy; Frédéric Lepretre; Olivier Nibourel; Audrey Decambron; Eileen Mary Boyle; Aline Renneville; Sabine Tricot; Agnès Daudignon; Bruno Quesnel; Patrick Duthilleul; Claude Preudhomme; Xavier Leleu
Journal:  Clin Cancer Res       Date:  2015-10-21       Impact factor: 12.531

5.  The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients.

Authors:  Benjamin Terrier; Arnaud Jaccard; Jean-Luc Harousseau; Richard Delarue; Olivier Tournilhac; Mathilde Hunault-Berger; Mohamed Hamidou; Jacques Dantal; Marc Bernard; Bernard Grosbois; Pierre Morel; Valérie Coiteux; Olivier Gisserot; Philippe Rodon; Arnaud Hot; Caroline Elie; Véronique Leblond; Jean-Paul Fermand; Fadi Fakhouri
Journal:  Medicine (Baltimore)       Date:  2008-03       Impact factor: 1.889

6.  Genetics and cytogenetics of Waldenstrom's macroglobulinemia.

Authors:  Roelandt F J Schop; Rafael Fonseca
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

7.  Genomic abnormalities of Waldenström macroglobulinemia and related low-grade B-cell lymphomas.

Authors:  Esteban Braggio; Rafael Fonseca
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-03-09

Review 8.  Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenström's macroglobulinemia.

Authors:  Sigbjørn Berentsen
Journal:  Clin Lymphoma Myeloma       Date:  2009-03

Review 9.  Waldenström's macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia.

Authors:  Marvin J Stone
Journal:  Clin Lymphoma Myeloma       Date:  2009-03

10.  Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.

Authors:  Steven P Treon; Christina Tripsas; Christina Hanzis; Leukothea Ioakimidis; Christopher J Patterson; Robert J Manning; Patricia Sheehy; Barry Turnbull; Zachary R Hunter
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-10-17
View more
  15 in total

1.  Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.

Authors:  Zachary R Hunter; Lian Xu; Nickolas Tsakmaklis; Maria G Demos; Amanda Kofides; Cristina Jimenez; Gloria G Chan; Jiaji Chen; Xia Liu; Manit Munshi; Joshua Gustine; Kirsten Meid; Christopher J Patterson; Guang Yang; Toni Dubeau; Mehmet K Samur; Jorge J Castillo; Kenneth C Anderson; Nikhil C Munshi; Steven P Treon
Journal:  Blood Adv       Date:  2018-11-13

2.  Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.

Authors:  Stephanie Guidez; Julien Labreuche; Elodie Drumez; Loic Ysebaert; Jana Bakala; Caroline Delette; Bénédicte Hivert; Caroline Protin; Hervé Declercq; Mélanie Verlay; Jean Pierre Marolleau; Alain Duhamel; Pierre Morel
Journal:  Blood Adv       Date:  2018-11-27

3.  Imaging spectrum of Bing-Neel syndrome: how can a radiologist recognise this rare neurological complication of Waldenström's macroglobulinemia?

Authors:  Aikaterini Fitsiori; Luc-Matthieu Fornecker; Laurence Simon; Alexandros Karentzos; Damien Galanaud; Olivier Outteryck; Patrick Vermersch; Jean-Pierre Pruvo; Emmanuel Gerardin; Christine Lebrun-Frenay; Francois Lafitte; Jean-Philippe Cottier; Christine Clerc; Jerome de Seze; Jean-Louis Dietemann; Stephane Kremer
Journal:  Eur Radiol       Date:  2018-06-19       Impact factor: 5.315

Review 4.  Toward personalized treatment in Waldenström macroglobulinemia.

Authors:  Jorge J Castillo; Steven P Treon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

5.  Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia.

Authors:  Mark Bustoros; Romanos Sklavenitis-Pistofidis; Prashant Kapoor; Chia-Jen Liu; Efstathios Kastritis; Saurabh Zanwar; Geoffrey Fell; Jithma P Abeykoon; Kalvis Hornburg; Carl Jannes Neuse; Catherine R Marinac; David Liu; Jenny Soiffer; Maria Gavriatopoulou; Cody Boehner; Joseph M Cappuccio; Henry Dumke; Kaitlen Reyes; Robert J Soiffer; Robert A Kyle; Steven P Treon; Jorge J Castillo; Meletios A Dimopoulos; Stephen M Ansell; Lorenzo Trippa; Irene M Ghobrial
Journal:  J Clin Oncol       Date:  2019-04-16       Impact factor: 44.544

Review 6.  Management of Waldenström macroglobulinemia in 2020.

Authors:  Jorge J Castillo; Steven P Treon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

7.  Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.

Authors:  Sæmundur Rögnvaldsson; Thorvardur Jon Love; Sigrun Thorsteinsdottir; Elín Ruth Reed; Jón Þórir Óskarsson; Íris Pétursdóttir; Guðrún Ásta Sigurðardóttir; Brynjar Viðarsson; Páll Torfi Önundarson; Bjarni A Agnarsson; Margrét Sigurðardóttir; Ingunn Þorsteinsdóttir; Ísleifur Ólafsson; Ásdís Rósa Þórðardóttir; Elías Eyþórsson; Ásbjörn Jónsson; Andri S Björnsson; Gunnar Þór Gunnarsson; Runólfur Pálsson; Ólafur Skúli Indriðason; Gauti Kjartan Gíslason; Andri Ólafsson; Guðlaug Katrín Hákonardóttir; Manje Brinkhuis; Sara Lovísa Halldórsdóttir; Tinna Laufey Ásgeirsdóttir; Hlíf Steingrímsdóttir; Ragnar Danielsen; Inga Dröfn Wessman; Petros Kampanis; Malin Hulcrantz; Brian G M Durie; Stephen Harding; Ola Landgren; Sigurður Yngvi Kristinsson
Journal:  Blood Cancer J       Date:  2021-05-17       Impact factor: 11.037

8.  Role of IRF4 in resistance to immunomodulatory (IMid) compounds® in Waldenström's macroglobulinemia.

Authors:  Elisabeth Bertrand; Nathalie Jouy; Salomon Manier; Guillemette Fouquet; Stéphanie Guidez; Eileen Boyle; Stéphanie Noel; Cécile Tomowiak; Charles Herbaux; Susanna Schraen; Claude Preudhomme; Bruno Quesnel; Stéphanie Poulain; Xavier Leleu
Journal:  Oncotarget       Date:  2017-12-04

9.  Idelalisib in a patient with refractory Waldenström's macroglobulinemia complicated by anuric renal failure: a case report.

Authors:  M D'Aveni-Piney; M Divoux; H Busby-Venner; M Muller; J Broséus; P Feugier
Journal:  J Med Case Rep       Date:  2018-06-12

Review 10.  Current applications of multiparameter flow cytometry in plasma cell disorders.

Authors:  T Jelinek; R Bezdekova; M Zatopkova; L Burgos; M Simicek; T Sevcikova; B Paiva; R Hajek
Journal:  Blood Cancer J       Date:  2017-10-20       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.